Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, Poirier P, Reoch J, Eisenberg MJ.

Am J Med. 2012 Feb;125(2):126-33. doi: 10.1016/j.amjmed.2011.08.025. Review.

PMID:
22269613
[PubMed - indexed for MEDLINE]
2.

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

Wilding JP.

Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Epub 2012 Apr 23. Review.

PMID:
22443197
[PubMed - indexed for MEDLINE]
3.

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.

PMID:
16168052
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
[PubMed - indexed for MEDLINE]
5.

Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.

Fruchart JC.

Cardiovasc Diabetol. 2013 May 31;12:82. doi: 10.1186/1475-2840-12-82. Review.

PMID:
23721199
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.

PMID:
17519293
[PubMed - indexed for MEDLINE]
7.

Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).

Huang TH, Roufogalis BD.

Curr Mol Pharmacol. 2012 Jun;5(2):241-7. Review.

PMID:
22122453
[PubMed - indexed for MEDLINE]
8.

Examining the safety of PPAR agonists - current trends and future prospects.

Bortolini M, Wright MB, Bopst M, Balas B.

Expert Opin Drug Saf. 2013 Jan;12(1):65-79. doi: 10.1517/14740338.2013.741585. Epub 2012 Nov 8. Review.

PMID:
23134541
[PubMed - indexed for MEDLINE]
9.

PPAR dual agonists: are they opening Pandora's Box?

Balakumar P, Rose M, Ganti SS, Krishan P, Singh M.

Pharmacol Res. 2007 Aug;56(2):91-8. Epub 2007 Mar 14. Review.

PMID:
17428674
[PubMed - indexed for MEDLINE]
10.

Fibrates, glitazones, and peroxisome proliferator-activated receptors.

Lalloyer F, Staels B.

Arterioscler Thromb Vasc Biol. 2010 May;30(5):894-9. doi: 10.1161/ATVBAHA.108.179689. Review.

PMID:
20393155
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.

Nicholls SJ, Uno K.

Diab Vasc Dis Res. 2012 Apr;9(2):89-94. doi: 10.1177/1479164112441477. Epub 2012 Mar 9. Review.

PMID:
22407927
[PubMed - indexed for MEDLINE]
Free Article
12.

PPAR agonists and the metabolic syndrome.

Staels B.

Therapie. 2007 Jul-Aug;62(4):319-26. Epub 2007 Nov 6. Review.

PMID:
17983557
[PubMed - indexed for MEDLINE]
13.

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

Pershadsingh HA.

Expert Opin Investig Drugs. 2004 Mar;13(3):215-28. Review.

PMID:
15013941
[PubMed - indexed for MEDLINE]
14.

Reassessing the cardiovascular risks and benefits of thiazolidinediones.

Zinn A, Felson S, Fisher E, Schwartzbard A.

Clin Cardiol. 2008 Sep;31(9):397-403. doi: 10.1002/clc.20312. Review.

PMID:
18781598
[PubMed - indexed for MEDLINE]
15.

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.

Cox SL.

Drugs Today (Barc). 2005 Sep;41(9):579-87. Review.

PMID:
16341289
[PubMed - indexed for MEDLINE]
16.

Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643.

Zahradka P.

Cardiovasc Drug Rev. 2007 Summer;25(2):99-122. Review.

PMID:
17614934
[PubMed - indexed for MEDLINE]
17.

Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.

Fogo AB.

Curr Opin Nephrol Hypertens. 2008 May;17(3):282-5. doi: 10.1097/MNH.0b013e3282f9b1c0. Review.

PMID:
18408479
[PubMed - indexed for MEDLINE]
18.

Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.

Tseng CH, Tseng FH.

J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368-402. doi: 10.1080/10590501.2012.735519. Review.

PMID:
23167631
[PubMed - indexed for MEDLINE]
19.

The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.

Stafylas PC, Sarafidis PA, Lasaridis AN.

Int J Cardiol. 2009 Jan 24;131(3):298-304. doi: 10.1016/j.ijcard.2008.06.005. Epub 2008 Aug 5. Review.

PMID:
18684530
[PubMed - indexed for MEDLINE]
20.

Strategies for the development of new PPAR agonists in diabetes.

Cavender MA, Nicholls SJ, Lincoff AM.

Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S32-7. doi: 10.1097/01.hjr.0000368196.17109.5e. Review.

PMID:
20489419
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk